ExodusPoint Capital Management LP boosted its position in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 175.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 86,909 shares of the biotechnology company’s stock after purchasing an additional 55,308 shares during the period. ExodusPoint Capital Management LP owned about 0.11% of Coherus BioSciences worth $594,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its position in shares of Coherus BioSciences by 6.9% during the 3rd quarter. Ensign Peak Advisors Inc now owns 21,490 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 1,390 shares during the last quarter. Federated Hermes Inc. boosted its stake in Coherus BioSciences by 55.0% in the third quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company’s stock worth $41,000 after buying an additional 1,498 shares in the last quarter. Mackenzie Financial Corp boosted its position in Coherus BioSciences by 4.7% during the first quarter. Mackenzie Financial Corp now owns 33,671 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 1,509 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in Coherus BioSciences by 11.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 16,978 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,800 shares during the last quarter. Finally, American International Group Inc. lifted its position in Coherus BioSciences by 5.6% in the second quarter. American International Group Inc. now owns 39,212 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 2,067 shares during the last quarter. 91.86% of the stock is owned by institutional investors.
Coherus BioSciences Trading Up 1.8 %
Shares of CHRS stock opened at $4.98 on Thursday. Coherus BioSciences, Inc. has a 12-month low of $3.60 and a 12-month high of $11.01. The firm’s 50 day moving average is $4.66 and its 200 day moving average is $5.63. The stock has a market capitalization of $470.45 million, a P/E ratio of -1.50 and a beta of 0.88.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the stock. StockNews.com began coverage on shares of Coherus BioSciences in a report on Thursday, August 17th. They issued a “hold” rating on the stock. Barclays decreased their target price on Coherus BioSciences from $13.00 to $8.00 in a research report on Tuesday, May 23rd. HC Wainwright reduced their target price on shares of Coherus BioSciences from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Citigroup initiated coverage on shares of Coherus BioSciences in a research report on Monday, July 24th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Maxim Group reduced their target price on shares of Coherus BioSciences from $15.00 to $12.00 in a research report on Friday, May 12th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Coherus BioSciences has an average rating of “Moderate Buy” and an average target price of $14.63.
View Our Latest Report on Coherus BioSciences
About Coherus BioSciences
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States.
Further Reading
- Five stocks we like better than Coherus BioSciences
- 3 Grocery Stocks That Are Proving They Are Still Essential
- These Quality Dividend Kings Grow their Dividends the Fastest
- Why Are Stock Sectors Important to Successful Investing?
- 3 Growth Stocks to Buy in September
- What Investors Need to Know to Beat the Market
- 3 Underappreciated Stocks with Nowhere to Go But Up
Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report).
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
